PD-1抑制剂在胃癌的免疫治疗中的应用  

Application of PD-1 inhibitor in immunotherapy of gastric cancer

作　　者：冒春燕(综述) 丛辉(审校)[1,3] MAO Chunyan;CONG Hui(Department of Laboratory Medicine,Affiliated Hospital of Nantong University,Nantong,Jiangsu 226001,China;Medical School of Nantong University,Nantong,Jiangsu 226001,China;Department of Blood Transfusion,Affiliated Hospital of Nantong University,Nantong,Jiangsu 226001,China)

机构地区：[1]南通大学附属医院医学检验科,江苏南通226001 [2]南通大学医学院,江苏南通226001 [3]南通大学附属医院输血科,江苏南通226001

出　　处：《检验医学与临床》2024年第3期410-413,共4页Laboratory Medicine and Clinic

基　　金：江苏省卫生健康委员会重点项目(ZD2022008)。

摘　　要：近年来胃癌的发病率不断提高,80%的患者确诊时已到中晚期。目前新兴的胃癌免疫治疗法是治疗晚期胃癌的一种很有前景的治疗手段,国内外已经推出的细胞程序性死亡受体-1(PD-1)和细胞程序性死亡配体-1(PD-L1)抑制剂是继细胞毒T淋巴细胞抗原4后最重要的免疫学检查点抑制剂。PD-1单抗药纳武利尤单抗和帕博丽珠单抗主要用于胃癌的后线治疗,本文主要对帕博丽珠单抗和纳武利尤单抗在胃癌免疫治疗中的地位和价值展开综述。The incidence rate of gastric cancer has been increasing in recent years,and 80%patients are already in the middle or late stage when they are diagnosed.At present,the emerging immunotherapy for gastric cancer is a promising treatment mean for advanced gastric cancer,and programmed cell death receptor-1(PD-1)and programmed cell death ligand-1(PD-L1)inhibitors have been launched at home and abroad,which are the most important immunological checkpoint inhibitors after cytotoxic T lymphocyte-associated antigen-4.The PD-1 monoclonal antibody drugs,like Nivolumab and Pembrolizumab,are primarily used as later-line therapies for gastric cancer,and this article reviews the status and value of pembrolizumab and nivolumab in the immunotherapy of gastric cancer.

关 键 词：胃癌 免疫治疗 细胞程序性死亡受体-1 帕博丽珠单抗 纳武利尤单抗 

分 类 号：R735.2[医药卫生—肿瘤]